Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Pegvisomant (Somavert) vs Plecanatide (Trulance)
An educational, source-based comparison of Pegvisomant (Somavert) and Plecanatide (Trulance) — how each peptide works, what it's researched for, and what to know before going deeper.
Pegylated GH receptor antagonist for acromegaly.
Genetically engineered analog of human GH with site-directed mutations blocking functional dimerization of the GH receptor; pegylation extends half-life. Lowers IGF-1 without lowering GH.
- Acromegaly inadequately controlled by surgery, radiation, or somatostatin analogs
- • FDA-approved.
- • Monitor LFTs; tumor monitoring via MRI required.
- • Lipohypertrophy at injection sites.
Synthetic analog of human uroguanylin that activates guanylate cyclase-C in a pH-dependent manner, increasing intestinal fluid secretion and transit.
- Chronic idiopathic constipation
- IBS-C
- • FDA-approved.
- • Diarrhea most common adverse event.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Pegvisomant (Somavert) | Pegvisomant long-term acromegaly control | Lancet | 2001 | IGF-1 normalization in >90% on adequate doses. |
| Plecanatide (Trulance) | Plecanatide phase 3 | American Journal of Gastroenterology | 2017 | Significantly improved complete spontaneous bowel movements vs placebo. |
Side-effect & safety grid
- FDA-approved.
- Monitor LFTs; tumor monitoring via MRI required.
- Lipohypertrophy at injection sites.
- FDA-approved.
- Diarrhea most common adverse event.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Pegvisomant (Somavert) vs Plecanatide (Trulance) — Key differences
- Class: Pegvisomant (Somavert) is classified as GH Receptor Antagonist · Endocrine, while Plecanatide (Trulance) is GC-C Agonist · Gastrointestinal.
- Primary research focus: Pegvisomant (Somavert) — acromegaly inadequately controlled by surgery, radiation, or somatostatin analogs; Plecanatide (Trulance) — chronic idiopathic constipation.
- Tag: FDA-Approved · Endocrine vs FDA-Approved · GI.